JEN1 Antibody

What is JEN1 and why is it significant for research?

JEN1 is a monocarboxylate transporter found in Saccharomyces cerevisiae (baker's yeast) with 12 transmembrane domains and cytoplasm-facing N and C termini. It serves as the sole transporter responsible for pyruvate uptake in yeast cells, making it essential for cell growth in media containing pyruvate as the sole carbon source .

The significance of JEN1 lies in its role as a model system for studying membrane protein trafficking, endocytosis, and nutrient-responsive regulation. JEN1's glucose-induced endocytic degradation depends on the Snf1-glucose signaling pathway, making it valuable for investigating cellular responses to changing nutrient conditions . This transporter has become an important research target for understanding fundamental cellular processes including ubiquitin-mediated protein degradation and α-arrestin regulation of membrane proteins.

What are the key structural features of JEN1 relevant for antibody development?

JEN1's structure includes several domains that are particularly important for antibody development:

• Transmembrane domains: TMHMM analysis predicts 12 transmembrane domains, creating a challenge for generating antibodies against native conformations .

• N-terminal region (amino acids 2-94): This cytoplasmic domain plays a role in endocytosis regulation but is less critical than the C-terminal region .

• C-terminal region (amino acids 574-616): This region contains:

  • Recognition motifs for α-arrestin Rod1 association

  • Lysine residues critical for glucose-induced ubiquitination

  • Key regulatory elements that function as a glucose-responding degron

• Functional core domain: The central portion of the protein retains transport activity even when terminal regions are modified, making it a potential target for antibodies that don't interfere with function .

For successful antibody development, researchers should consider targeting epitopes in the N or C-terminal regions that are accessible in the native protein conformation while avoiding the transmembrane domains that may only be exposed under denaturing conditions.

How does the glucose-induced trafficking of JEN1 affect experimental design when using JEN1 antibodies?

The glucose-responsive trafficking of JEN1 significantly impacts experimental design when using JEN1 antibodies. In the presence of lactate, JEN1 localizes to the plasma membrane, but rapidly internalizes and degrades following glucose addition . This dynamic localization pattern requires careful consideration:

• Timing considerations: Experiments must account for rapid changes in JEN1 localization. Within 120 minutes of glucose exposure, wild-type JEN1 is almost completely degraded, while mutants lacking the C-terminal region (JEN1ΔC) remain stable at the plasma membrane .

• Sample preparation protocols:

  • For detecting total JEN1 levels: Harvest cells quickly and use protease inhibitors to prevent degradation during processing

  • For membrane-localized JEN1: Use subcellular fractionation in glucose-free conditions

  • For internalized JEN1: Consider time-course experiments following glucose addition

• Fixation methods: Choose fixation protocols that preserve JEN1 localization at specific trafficking stages

• Control selection: Include rod1Δ mutant cells as controls, as they show stabilized JEN1 even in glucose conditions

• Antibody validation: Verify antibody specificity against both native and ubiquitinated forms of JEN1, as ubiquitination alters protein migration patterns in immunoblots

How can JEN1 antibodies be used to study the relationship between ubiquitination and endocytosis?

JEN1 antibodies can be strategically employed to investigate the relationship between ubiquitination and endocytosis through several advanced approaches:

• Co-immunoprecipitation studies: Use JEN1 antibodies to pull down protein complexes and detect associated ubiquitination machinery components. This approach revealed that the C-terminal region of JEN1 is critical for its ubiquitination .

• Western blot analysis with ubiquitin detection:

  • Immunoprecipitate JEN1 using specific antibodies

  • Probe with anti-ubiquitin antibodies to detect ubiquitinated forms

  • Compare wild-type JEN1 with mutants (JEN1ΔN, JEN1ΔC) to identify regions required for ubiquitination

• Live-cell imaging with fluorescent antibodies: Track the temporal relationship between JEN1 ubiquitination and endocytosis in real-time using cell-permeable antibody fragments

• Proximity ligation assays: Detect in situ interactions between JEN1 and ubiquitination machinery components using antibody pairs

• Quantitative analysis of ubiquitination patterns: Compare ubiquitination profiles between wild-type and mutant JEN1 forms. As shown in studies, ubiquitin-positive bands are clearly detected in wild-type JEN1 and JEN1ΔN cells but only faint signals are observed in JEN1ΔC cells .

This methodological approach revealed that the C-terminal 20-amino-acid region of JEN1 contains both the recognition sequence for α-arrestin Rod1 and the lysine residues required for glucose-induced ubiquitination, functioning as a glucose-responding degron .

What methodologies can be used to analyze JEN1 antibody specificity and cross-reactivity?

Analyzing JEN1 antibody specificity and cross-reactivity requires rigorous validation using multiple complementary approaches:

• Western blot analysis against recombinant proteins:

  • Test against full-length JEN1, JEN1ΔN, JEN1ΔC, and JEN1ΔNC variants

  • Include negative controls (lysates from jen1Δ cells)

  • Evaluate cross-reactivity with related transporters

• Enzyme-linked immunosorbent assay (ELISA):

  • Perform titration assays starting at 10 μg/ml with five-fold serial dilutions

  • Use secondary antibody (e.g., goat anti-human IgG conjugated to peroxidase) at 1:10,000 dilution

  • Include technical and biological duplicates to ensure reproducibility

• Immunofluorescence microscopy validation:

  • Compare staining patterns in wild-type versus jen1Δ cells

  • Evaluate co-localization with GFP-tagged JEN1 expressed from its native promoter

  • Test fixation conditions that preserve epitope accessibility

• Single-cell protein analysis techniques:

  • Apply computational correction methods like ADTGP (using Gaussian process regression) to account for technical noise in antibody-based detection

  • Model protein expression distribution conditioned on equal isotype control counts

• Epitope mapping:

  • Use peptide arrays covering overlapping segments of JEN1 sequence

  • Identify specific binding regions and potential cross-reactive epitopes

  • Confirm findings with competitive binding assays

For validation experiments, include both positive controls (known JEN1-expressing conditions like lactate media) and negative controls (jen1Δ mutants and glucose-repressed samples) to establish detection limits and specificity thresholds.

How can advanced AI technologies be integrated into JEN1 antibody design and optimization?

Advanced AI technologies offer significant potential for JEN1 antibody design and optimization through several innovative approaches:

• De novo CDRH3 sequence design:

  • AI algorithms can generate antigen-specific antibody CDRH3 sequences using germline-based templates

  • This bypasses the complexity of natural antibody generation while mimicking its outcome

  • The approach has been validated for other targets such as SARS-CoV-2, demonstrating potential applicability to JEN1

• Structural prediction and epitope optimization:

  • AI models can predict the structure of JEN1 and identify optimal epitopes for antibody targeting

  • Focus on regions with high antigenicity and accessibility, particularly the N and C-terminal domains

  • Design antibodies that specifically recognize critical functional regions (e.g., the C-terminal degron)

• Affinity maturation simulation:

  • AI can simulate somatic hypermutation to improve antibody affinity

  • Identify candidate mutations that enhance binding without compromising specificity

  • Predict stability and manufacturability of optimized antibodies

• Computational validation workflows:

  • Use AI to predict cross-reactivity with related transporters

  • Model binding energetics and interaction dynamics

  • Simulate antibody performance across different experimental conditions

• Integration with experimental data:

  • Use Gaussian process regression similar to ADTGP for analyzing antibody performance

  • Correct for droplet-specific technical noise in single-cell protein sequencing data

  • Improve interpretability by modeling protein expression distribution

Implementation requires:

• Training datasets combining sequence, structural, and functional data

• Computational infrastructure for model training and validation

• Experimental validation of AI-designed antibodies through expression and binding assays

This integrated approach can significantly reduce development time while improving specificity and functionality of JEN1 antibodies for research applications.

What are the optimal protocols for JEN1 antibody production and purification?

The optimal protocols for JEN1 antibody production and purification involve several critical steps:

• Antibody construct design:

  • Insert variable genes into bi-cistronic plasmids encoding constant regions for heavy chain and either kappa or lambda light chain

  • Consider optimizing codon usage for expression system

  • For monoclonal antibody production, validate sequence through DNA sequencing

• Expression system selection:

  • Expi293F cells in FreeStyle F17 expression media supplemented with 0.1% Pluronic Acid F-68 and 20% 4mM L-glutamine

  • Transfect using Expifectamine transfection reagents for optimal expression

  • Maintain cultures with shaking at 8% CO₂ saturation and 37°C for 5 days

• Harvest and initial processing:

  • Harvest cultures after 5 days post-transfection

  • Centrifuge at minimum 6000 rpm for 20 minutes

  • Filter supernatant using Nalgene Rapid Flow Disposable Filter Units with PES membrane (0.45 or 0.22 μm)

• Purification procedure:

  • Run filtered supernatant over PBS-equilibrated columns containing 1 ml of Protein A agarose resin

  • Following binding phase, wash columns with PBS

  • Elute purified antibodies with 5 mls of 100 mM Glycine HCl at pH 2.7 directly into 1 mL of 1 M Tris-HCl pH 8

  • Buffer exchange into PBS for final formulation

• Quality control testing:

  • Validate antibody purity by SDS-PAGE

  • Confirm specificity through Western blot against JEN1-expressing yeast extracts

  • Perform functional binding assays to verify activity

  • Test lot-to-lot consistency through standardized assays

This methodology has been successfully applied for antibody production against other targets and can be adapted specifically for JEN1 antibodies with appropriate antigen selection based on the unique structural features of JEN1 .

How should researchers design experiments to study JEN1-Rod1 interactions using antibodies?

Designing experiments to study JEN1-Rod1 interactions requires careful planning and specific methodological approaches:

• Co-immunoprecipitation (Co-IP) assays:

  • Use anti-JEN1 antibodies to pull down complexes from yeast lysates

  • Probe for Rod1 in immunoprecipitates to detect interaction

  • Include controls with JEN1ΔC mutants, which show impaired Rod1 interaction

  • Test interaction under different conditions (lactate vs. glucose media)

• Proximity-based interaction assays:

  • Use split-reporter systems (e.g., split-GFP) fused to JEN1 and Rod1

  • Apply bimolecular fluorescence complementation (BiFC) to visualize interactions

  • Confirm findings with proximity ligation assay (PLA) using antibodies against both proteins

• Domain mapping experiments:

  • Generate a panel of JEN1 truncation mutants focusing on the C-terminal region

  • Test interaction with Rod1 using Co-IP or yeast two-hybrid assays

  • Identify specific amino acid sequences required for association with Rod1

  • Create fusion proteins with other transporters (e.g., Mup1) to test transferability of the interaction domain

• Temporal dynamics analysis:

  • Design time-course experiments following glucose addition

  • Synchronize JEN1 trafficking using temperature-sensitive endocytosis mutants

  • Track Rod1 recruitment, JEN1 ubiquitination, and endocytosis sequentially

• In vitro binding assays:

  • Express and purify recombinant JEN1 C-terminal fragments and Rod1

  • Perform in vitro binding assays to determine direct interaction

  • Measure binding kinetics and affinity using surface plasmon resonance

When interpreting results, consider that JEN1-Rod1 interaction is regulated by glucose signaling pathways and may depend on post-translational modifications of both proteins. The C-terminal 20-amino-acid region of JEN1 has been identified as critical for this interaction, functioning as a glucose-responding degron for α-arrestin-mediated endocytic degradation .

What methods are recommended for detecting and quantifying JEN1 ubiquitination patterns?

Detecting and quantifying JEN1 ubiquitination patterns requires specialized techniques that can capture this transient post-translational modification:

• Immunoprecipitation-based ubiquitination detection:

  • Express JEN1-GFP in vrp1Δ yeast cells (endocytosis defective) to stabilize ubiquitinated forms

  • Immunoprecipitate JEN1 using GFP antibodies under denaturing conditions

  • Detect ubiquitination by immunoblotting with anti-ubiquitin antibodies

  • Compare wild-type JEN1 with JEN1ΔN and JEN1ΔC variants to identify key ubiquitination regions

• Site-specific ubiquitination analysis:

  • Generate lysine-to-arginine mutants of potential ubiquitination sites in JEN1's C-terminal region

  • Analyze ubiquitination patterns of mutants compared to wild-type

  • Identify critical lysine residues required for glucose-induced degradation

  • Confirm findings with mass spectrometry to identify exact ubiquitination sites

• Quantitative ubiquitination profiling:

  • Use tandem ubiquitin binding entities (TUBEs) to enrich ubiquitinated proteins

  • Apply stable isotope labeling (SILAC) to compare ubiquitination levels between conditions

  • Employ targeted proteomics to quantify specific ubiquitin chain types (K48 vs. K63)

• Fluorescence-based ubiquitination sensors:

  • Develop FRET-based sensors between JEN1 and ubiquitin

  • Monitor ubiquitination in real-time during glucose-induced endocytosis

  • Correlate ubiquitination dynamics with JEN1 trafficking

• Mass spectrometry analysis:

  • Purify JEN1 under native or denaturing conditions

  • Identify ubiquitination sites and chain types using mass spectrometry

  • Quantify relative abundance of differently modified forms

  • Compare profiles between wild-type and mutant variants

Research has shown that ubiquitin-positive bands are clearly detected in wild-type JEN1 and JEN1ΔN cells but only faint signals are observed in JEN1ΔC cells, confirming the critical role of the C-terminal region in JEN1 ubiquitination . These methodologies can help researchers precisely map and quantify JEN1 ubiquitination patterns under various conditions.

How can researchers address technical noise in JEN1 antibody-based single-cell protein analysis?

Addressing technical noise in JEN1 antibody-based single-cell protein analysis requires sophisticated computational and experimental approaches:

• Apply Gaussian process regression correction:

  • Implement ADTGP (or similar) R packages to correct for droplet-specific technical noise

  • Model protein expression distribution conditioned on equal isotype control counts

  • This approach improves data interpretability by accounting for unbound antibody encapsulation during droplet generation

• Optimize isotype control usage:

  • Include appropriate isotype control antibodies in all experiments

  • Use control antibodies that match the species, isotype, and concentration of your JEN1 antibody

  • Track correlation of isotype control signals between cells to identify technical artifacts

• Implement experimental controls:

  • Include jen1Δ knockout samples to establish background signal levels

  • Prepare samples with known JEN1 expression levels as calibration standards

  • Process technical replicates to distinguish biological variability from technical noise

• Data preprocessing techniques:

  • Apply count normalization methods appropriate for antibody-based data

  • Use background correction algorithms specifically designed for protein expression data

  • Implement batch effect correction when combining data from multiple experiments

• Visualization and validation approaches:

  • Create scatter plots of protein counts versus isotype control counts to identify correlations

  • Use before/after correction comparisons to validate noise reduction

  • Verify biological findings with orthogonal methods (flow cytometry, immunoblotting)

When interpreting the corrected data, researchers should be aware that strong correlations between negative control antibodies across cells is a hallmark of technical noise from unbound antibody encapsulation .

What are common pitfalls in JEN1 antibody experiments and how can they be overcome?

Researchers working with JEN1 antibodies may encounter several common pitfalls that can be addressed through specific methodological approaches:

• Inconsistent detection of JEN1 in different growth conditions:

  • Problem: JEN1 expression is strongly regulated by carbon source, with repression in glucose and induction in lactate/pyruvate

  • Solution: Carefully standardize growth conditions and carbon sources; use fluoropyruvate sensitivity assays to confirm functional JEN1 expression

  • Verification: Include controls with known JEN1 expression (lactate-grown wild-type cells as positive control)

• Difficulty detecting native JEN1 in yeast samples:

  • Problem: Low abundance and membrane localization can reduce detection sensitivity

  • Solution: Enrich membrane fractions before analysis; use GFP-tagged JEN1 for enhanced detection

  • Verification: Compare localization patterns with published fluorescence microscopy data

• False negatives in ubiquitination detection:

  • Problem: Ubiquitinated JEN1 is rapidly degraded, leading to low abundance

  • Solution: Use endocytosis-defective mutants like vrp1Δ to stabilize ubiquitinated forms

  • Verification: Observe slower-migrating bands in immunoblots that react with both anti-JEN1 and anti-ubiquitin antibodies

• Non-specific antibody binding:

  • Problem: Cross-reactivity with other membrane transporters

  • Solution: Validate specificity using jen1Δ knockout controls; perform competitive binding assays

  • Verification: Absence of signal in jen1Δ samples confirms specificity

• Difficulties recreating Rod1-JEN1 interactions in vitro:

  • Problem: Interactions may depend on specific post-translational modifications

  • Solution: Use physiologically relevant contexts (e.g., glucose-treated cells); include appropriate kinases and phosphatases in reaction buffers

  • Verification: Compare results with in vivo Co-IP experiments under similar conditions

• Inconsistent results between different detection methods:

  • Problem: Different epitope accessibility in various experimental conditions

  • Solution: Use multiple antibodies targeting different JEN1 regions; employ complementary detection methods

  • Verification: Concordance between methods increases confidence in results

By anticipating these challenges and implementing the recommended solutions, researchers can significantly improve the reliability and reproducibility of their JEN1 antibody experiments.

How should researchers interpret contradictory results between JEN1 antibody detection and functional assays?

When faced with contradictory results between JEN1 antibody detection and functional assays, researchers should apply a systematic approach to reconcile the discrepancies:

• Evaluate potential causes for discordance:

  • Post-translational modifications: Antibodies may detect total JEN1 but not distinguish active vs. inactive forms

  • Localization differences: JEN1 may be present (detectable by antibodies) but not properly localized (affecting function)

  • Protein conformation: Functional assays detect properly folded protein, while antibodies may recognize denatured epitopes

  • Detection sensitivity thresholds: Functional assays may require higher protein levels than immunodetection methods

• Conduct targeted experiments to resolve contradictions:

  • Subcellular fractionation: Separate plasma membrane, endosomal, and vacuolar fractions to track JEN1 localization

  • Domain-specific antibody panels: Use antibodies targeting different JEN1 regions to identify potential processing events

  • Correlation analysis: Quantitatively compare antibody signal intensity with transport activity across multiple samples

  • Mutational analysis: Test JEN1 variants that retain structure but lack function (e.g., JEN1ΔC maintains structure but shows impaired endocytosis)

• Decision matrix for result interpretation:

• Case study-based interpretation guide:

  • When JEN1ΔC is detected by antibodies at the plasma membrane but shows altered endocytosis in functional assays, this indicates the protein is structurally intact but regulatory mechanisms are compromised

  • JEN1ΔN showing fluoropyruvate sensitivity (functional) but altered trafficking patterns suggests the N-terminal region affects regulation but not core transport function

• Integrated data analysis approach:

  • Weight evidence based on methodological strengths and limitations

  • Consider alternative hypotheses that could explain all observations

  • Design definitive experiments that can discriminate between competing explanations

This systematic approach enables researchers to resolve apparent contradictions and develop a more complete understanding of JEN1 biology by integrating structural, functional, and regulatory insights.

How might JEN1 antibodies contribute to understanding broader mechanisms of membrane protein regulation?

JEN1 antibodies offer powerful tools for investigating fundamental mechanisms of membrane protein regulation that extend beyond yeast transporters:

• Comparative analysis of degron-mediated regulation:

  • Use JEN1 antibodies to immunoprecipitate regulatory complexes and identify shared components with other systems

  • Compare the C-terminal degron of JEN1 with similar regions in other transporters

  • The glucose-responding degron in JEN1's C-terminal region could serve as a model for nutrient-responsive regulatory mechanisms in diverse membrane proteins

• Arrestin recognition mechanisms:

  • Apply JEN1 antibodies in structural studies of arrestin-transporter complexes

  • Investigate how α-arrestins like Rod1 distinguish between different conformational states

  • Explore conservation of recognition mechanisms across species and protein families

• Integrated trafficking pathway mapping:

  • Develop antibodies against modified forms of JEN1 to track specific trafficking intermediates

  • Create temporal maps of protein complex assembly/disassembly during endocytosis

  • Connect findings to broader endocytic mechanisms conserved from yeast to humans

• Multi-level regulation paradigms:

  • Study how transcriptional, post-transcriptional, and post-translational mechanisms coordinate JEN1 regulation

  • Use antibodies to quantify protein levels in correlation with mRNA abundance and modification state

  • Develop systems biology models of integrated regulatory networks

• Evolutionary conservation analysis:

  • Apply JEN1 antibodies in comparative studies across fungal species

  • Identify conserved vs. species-specific regulatory mechanisms

  • Trace the evolution of nutrient-responsive trafficking systems

This research has potential implications for understanding human disease mechanisms, as similar regulatory principles govern many human transporters involved in nutrient uptake, drug transport, and signaling. The JEN1 system provides a tractable model for discovering fundamental principles that may apply to more complex human systems .

What emerging technologies might enhance the applications of JEN1 antibodies in research?

Several emerging technologies show particular promise for enhancing JEN1 antibody applications in research:

• Advanced imaging technologies:

  • Super-resolution microscopy: Track JEN1 clustering and nanodomain organization with 10-20nm resolution

  • Lattice light-sheet microscopy: Follow JEN1 trafficking in living cells with reduced phototoxicity

  • Correlative light and electron microscopy (CLEM): Connect fluorescence imaging with ultrastructural details of JEN1-containing complexes

• Single-molecule analysis techniques:

  • Single-molecule pull-down (SiMPull): Analyze JEN1 complex composition with single-molecule sensitivity

  • Single-molecule FRET: Study conformational changes in JEN1 during transport and trafficking

  • Zero-mode waveguides: Monitor real-time binding kinetics between JEN1 and regulatory proteins

• Advanced proteomics approaches:

  • Proximity labeling proteomics: Identify JEN1-proximal proteins using techniques like BioID or APEX

  • Crosslinking mass spectrometry: Map interaction interfaces between JEN1 and binding partners

  • Single-cell proteomics: Track JEN1 levels and modifications in individual cells during responses to nutrient changes

• AI-enhanced antibody development:

  • Structure-based epitope prediction: Design antibodies targeting functionally important JEN1 regions

  • AI-optimized CDRH3 sequences: Generate antibodies with enhanced specificity for JEN1 variants

  • Computational modeling of antibody-antigen interactions: Predict binding properties and optimize performance

• Integrated data analysis platforms:

  • Gaussian process regression tools like ADTGP: Correct for technical noise in antibody-based assays

  • Multi-modal data integration: Combine antibody-based detection with transcriptomics and metabolomics

  • Digital twin modeling: Create computational models of JEN1 regulation calibrated with experimental data

The integration of these technologies with traditional antibody applications will enable more comprehensive understanding of JEN1 biology and membrane protein regulation more broadly.

How can computational approaches improve JEN1 antibody research data analysis?

Computational approaches offer powerful methods to enhance JEN1 antibody research data analysis and interpretation:

• Advanced noise correction algorithms:

  • Implement Gaussian process regression methods like ADTGP to correct for technical noise in antibody-based detection

  • Model protein expression distributions conditioned on equal isotype control counts to improve data interpretability

  • Address the challenge of unbound antibody encapsulation during droplet generation in single-cell analysis

• Integrated multi-omics analysis:

  • Correlate JEN1 protein levels (detected by antibodies) with transcriptomic and metabolomic data

  • Apply machine learning algorithms to identify regulatory networks controlling JEN1 expression

  • Develop computational models that predict JEN1 function based on integrated datasets

• Structure-informed antibody binding prediction:

  • Use protein structure prediction algorithms to model JEN1 conformation

  • Identify optimal epitopes for antibody targeting based on accessibility and uniqueness

  • Predict how antibody binding might affect JEN1 function or interaction with partners

• Quantitative image analysis pipelines:

  • Develop automated algorithms for tracking JEN1 trafficking in microscopy data

  • Apply computer vision techniques to quantify co-localization with endocytic markers

  • Implement machine learning for classification of trafficking phenotypes

• Systematic antibody validation frameworks:

  • Design computational workflows for evaluating antibody specificity across diverse conditions

  • Implement statistical approaches for distinguishing specific from non-specific binding

  • Create standardized reporting formats for antibody validation data

• Temporal dynamics modeling:

  • Apply ordinary differential equation (ODE) models to describe JEN1 trafficking kinetics

  • Use parameter estimation algorithms to extract rate constants from experimental data

  • Build predictive models of how perturbations affect JEN1 regulation

These computational approaches not only improve data quality and interpretation but also enable integration of diverse experimental results into coherent models of JEN1 biology. Researchers should consider implementing the ADTGP R package or similar tools that can be installed from repositories like GitHub, requiring only protein raw counts, isotype control raw counts, and a design matrix to run effectively .